Praamstra P, Wevers R A, Gabreëls F J, Rotteveel J J, Renier W O, Sengers R C, Lamers K J
Institute of Neurology, University Hospital Nijmegen, The Netherlands.
Clin Neurol Neurosurg. 1990;92(2):143-8. doi: 10.1016/0303-8467(90)90090-r.
We discuss four cases of GM2-gangliosidosis. In one of them the biochemical diagnostic confirmation was difficult. This case revealed striking discrepancies between the results of different methods of enzyme assay. The hexosaminidase A determination based on pH inactivation is not always reliable; assay with natural substrate may be necessary. However, the results with the newly developed substrate 4-MU-GlcNac-6-SO4 are promising and it seems to be a good alternative to the traditional (pH or heat) inactivation procedures. The deficiency can be shown in leukocytes, plasma and fibroblasts with the 6-sulfated substrate. The carrier state seems better reflected in plasma hexosaminidase A than in leukocyte hexaminidase A levels.
我们讨论了4例GM2神经节苷脂沉积症病例。其中1例的生化诊断确认存在困难。该病例显示不同酶测定方法的结果之间存在显著差异。基于pH失活的己糖胺酶A测定并不总是可靠的;可能需要使用天然底物进行测定。然而,新开发的底物4-MU-GlcNac-6-SO4的测定结果很有前景,似乎是传统(pH或热)失活程序的良好替代方法。使用6-硫酸化底物可在白细胞、血浆和成纤维细胞中显示出该缺陷。与白细胞己糖胺酶A水平相比,血浆己糖胺酶A似乎能更好地反映携带者状态。